Our Beta Cell Therapy consortium was founded in 2002 with the mission of developing and implementing, through international collaboration, strategies and methods that restore an adequate mass of insulin-producing beta cells in patients with diabetes. In this long-term objective, a Research & Development Platform drives Clinical Trials, involving collaborations between numerous participants. A Coordination Unit guides translation to clinical and bio-industrial applications along a focused roadmap.